See more : Reach Resources Limited (RR1.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Intersect ENT, Inc. (XENT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intersect ENT, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- MasterCraft Boat Holdings, Inc. (MCFT) Income Statement Analysis – Financial Results
- forcelead (6996.TWO) Income Statement Analysis – Financial Results
- Veoneer, Inc. (VNE-SDB.ST) Income Statement Analysis – Financial Results
- Iffe Futura, S.A. (NAT.MC) Income Statement Analysis – Financial Results
- Wintest Corp. (6721.T) Income Statement Analysis – Financial Results
Intersect ENT, Inc. (XENT)
About Intersect ENT, Inc.
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.75M | 80.55M | 109.14M | 108.47M | 96.30M | 78.71M | 61.59M | 38.59M | 17.93M | 5.86M |
| Cost of Revenue | 30.01M | 30.31M | 21.77M | 22.61M | 15.50M | 13.00M | 12.29M | 10.22M | 8.15M | 3.84M |
| Gross Profit | 76.74M | 50.25M | 87.37M | 85.86M | 80.80M | 65.71M | 49.31M | 28.36M | 9.78M | 2.03M |
| Gross Profit Ratio | 71.89% | 62.38% | 80.05% | 79.15% | 83.91% | 83.48% | 80.05% | 73.51% | 54.55% | 34.56% |
| Research & Development | 27.94M | 19.35M | 24.28M | 19.26M | 18.36M | 18.89M | 16.61M | 10.33M | 9.52M | 9.26M |
| General & Administrative | 0.00 | 98.55M | 108.48M | 91.60M | 80.05M | 72.93M | 59.64M | 36.11M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 122.07M | 98.55M | 108.48M | 91.60M | 80.05M | 72.93M | 59.64M | 36.11M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.23M | 9.25M |
| Operating Expenses | 150.01M | 117.90M | 132.76M | 110.87M | 98.41M | 91.82M | 76.25M | 46.44M | 27.75M | 18.51M |
| Cost & Expenses | 180.02M | 148.21M | 154.54M | 133.48M | 113.90M | 104.82M | 88.53M | 56.67M | 35.90M | 22.35M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 125.00K | 7.00K | 156.00K |
| Interest Expense | 6.44M | 2.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 409.00K | 117.00K | 36.00K |
| Depreciation & Amortization | 4.81M | 2.84M | 3.90M | 1.88M | 1.46M | 1.17M | 826.00K | 583.00K | 505.00K | 351.00K |
| EBITDA | -150.08M | -67.14M | -39.09M | -21.04M | -14.90M | -24.06M | -25.81M | -17.37M | -17.75M | -15.98M |
| EBITDA Ratio | -140.59% | -83.35% | -35.82% | -19.39% | -15.47% | -30.56% | -41.90% | -45.02% | -98.97% | -272.52% |
| Operating Income | -154.89M | -67.65M | -45.39M | -25.01M | -17.60M | -26.11M | -26.94M | -18.08M | -17.97M | -16.49M |
| Operating Income Ratio | -145.10% | -83.98% | -41.59% | -23.05% | -18.28% | -33.17% | -43.74% | -46.85% | -100.20% | -281.17% |
| Total Other Income/Expenses | -6.44M | -5.08M | 2.40M | 2.08M | 1.24M | 889.00K | 306.00K | -284.00K | -403.00K | 120.00K |
| Income Before Tax | -161.33M | -72.74M | -42.99M | -22.92M | -16.36M | -25.22M | -26.63M | -18.36M | -18.37M | -16.37M |
| Income Before Tax Ratio | -151.13% | -90.29% | -39.39% | -21.13% | -16.99% | -32.05% | -43.24% | -47.59% | -102.44% | -279.12% |
| Income Tax Expense | -1.69M | -416.00K | 2.40M | 2.08M | 1.24M | 889.00K | 306.00K | 125.00K | -286.00K | 156.00K |
| Net Income | -159.64M | -72.32M | -42.99M | -22.92M | -16.36M | -25.22M | -26.63M | -18.36M | -18.37M | -16.37M |
| Net Income Ratio | -149.54% | -89.78% | -39.39% | -21.13% | -16.99% | -32.05% | -43.24% | -47.59% | -102.44% | -279.12% |
| EPS | -4.80 | -2.22 | -1.37 | -0.76 | -0.56 | -0.89 | -1.02 | -1.61 | -1.17 | -0.94 |
| EPS Diluted | -4.80 | -2.22 | -1.37 | -0.76 | -0.56 | -0.89 | -1.02 | -1.61 | -1.17 | -0.94 |
| Weighted Avg Shares Out | 33.27M | 32.62M | 31.39M | 30.31M | 29.12M | 28.42M | 26.16M | 11.38M | 15.66M | 17.47M |
| Weighted Avg Shares Out (Dil) | 33.27M | 32.62M | 31.39M | 30.31M | 29.12M | 28.42M | 26.16M | 11.38M | 15.66M | 17.47M |
Intersect ENT (XENT) Banks on SINUVA Sales Amid COVID-19 Woes
Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference
Intersect ENT Announces New Appointments to Executive Leadership Team
Intersect ENT, Inc.'s (XENT) CEO Tom West on Q3 2020 Results - Earnings Call Transcript
Intersect ENT to Report Third Quarter 2020 Financial Results
Intersect ENT to Report Second Quarter 2020 Financial Results
Intersect ENT to Report First Quarter 2020 Financial Results
Intersect ENT to Report Fourth Quarter and Year 2019 Financial Results
Intersect ENT to Report Third Quarter 2019 Financial Results
Intersect ENT to Report Second Quarter 2019 Financial Results
Source: https://incomestatements.info
Category: Stock Reports
What were the peak quarterly and annual revenues for Intersect ENT?
Intersect ENT’s peak quarterly revenue was $32.8M in 2018(q4). Intersect ENT peak revenue was $109.1M in 2019. Intersect ENT annual revenue for 2020 was 80.6M, -26.19% growth from 2019. Intersect ENT annual revenue for 2021 was 106.7M, 32.52% growth from 2020.
How did COVID-19 impact Intersect ENT’s financial results?
Through the pandemic months of 2020, Intersect ENT’s business suffered a huge revenue decline as a result of hospitals suspending elective surgical procedures and significantly reducing ENT office visits.